

Efficacy of Home-delivered Transcranial Direct Electrical Stimulation or Chronic Pain

NCT07211256

| | |
|------------|------------------------------|
| Status | RECRUITING |
| Phase | Not Applicable |
| Sponsor | Hospital Ambroise Paré Paris |
| Enrollment | 70 participants |

Key Eligibility Criteria

Inclusion (1)

- Chronic pain for at least 6 months Pain intensity $\geq 4/10$ on 0-10 NRS Pain present every day or nearly every day Neuropathic pain (DN4 score $\geq 4/10$) or nociplastic pain (Kosek et al Pain 2021) Patients previously treated with rTMS of the motor cortex in routine in our pain center but with only transient efficacy (ie, efficacy for less than one month, defined as pain intensity improved by at least 30 %) Affiliated to social security

Exclusion (1)

- Contraindications to tDCS as stated in the manufacturer brochure (ie, implantable device, severe cognitive disorders, epilepsy, skin problems where will placed the electrodes, arterial or venous thrombosis, thrombophlebitis, metallic intracranial implant, craniotomy, intracranial aneurysm, cerebral tumor, severe sleep disorders such as narcolepsia) Concomitant treatment which might increase the risk of epilepsy such as high doses opioids (≥ 140 mg morphine equivalent) or high doses tricyclic antidepressants (≥ 150 mg per day) Pregnancy or lactation Age below 18 or > 80 years Pending litigation related to pain Pain more severe than neuropathic or nociplastic pain requiring treatment Severe disease such as cancer Severe psychiatric condition (psychosis) Impossible to be followed for up to 3 months Participation in a recent protocol (less than 3 months) Psychoactive drug abuse

Locations (1 total)

Centre d'Evaluation et de Traitement de la douleur, INSERM U 987, Boulogne-Billancourt, Hauts de Seine, France